MRNA$25.75
Chart
Performance
Key Stats
AI MRNA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldModerna is a pioneering biotech company with significant long-term potential in mRNA technology. However, current financial performance shows a decline from peak COVID-19 vaccine revenues, leading to negative earnings and a cautious market sentiment. While thematic tailwinds for mRNA in various diseases are strong, the company faces challenges in translating this into consistent profitability. Technical indicators are mixed, suggesting a period of price discovery.
Thematic
Moderna is at the forefront of mRNA technology, which has broad applications beyond COVID-19, including vaccines for respiratory illnesses, infectious diseases, and potentially cancer therapies and rare diseases. The company's partnerships and pipeline indicate strong future growth potential.
Fundamental
Moderna's financials reflect a significant shift from its pandemic-driven boom. Revenue and earnings have declined sharply, resulting in negative profitability and free cash flow. While the balance sheet remains relatively strong with substantial cash reserves, the current valuation appears high given the recent financial performance.
Technical
Moderna's stock price has experienced a significant decline from its highs. While recent daily and hourly indicators show some signs of potential stabilization or minor upward movement, longer-term trends remain down. The stock is trading below key moving averages on longer timeframes, indicating prevailing downward pressure.
| Factor | Score |
|---|---|
| mRNA Technology Versatility | 95 |
| Public Health & Pandemic Preparedness | 70 |
| Biotechnology Innovation | 85 |
| Partnerships & Collaborations | 80 |
| Market Adoption of Novel Therapies | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 15 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 60 |
| Support & Resistance | 50 |
| Volume Analysis | 50 |
| Short-Term Moving Averages | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Cash Position
The company maintains substantial cash and cash equivalents of $1.927 billion (as of Q4 2024), providing ample liquidity to fund operations and future investments.
Revenue Growth in Recent Quarters
Revenue showed positive growth in Q3 2024 ($1.855B) and Q4 2024 ($0.956B), indicating a rebound after a period of decline.
Bearish Points (7)
Negative Earnings Per Share (EPS)
The company has consistently reported negative EPS (e.g., -2.52 in Q2 2025, -2.91 in Q1 2025) with significant negative surprises in some quarters, indicating substantial losses.
Significant Net Losses
Net income for 2024 ($3.199B revenue) was negative at -$3.561 billion, with a net margin of -111.3%. This trend of negative net income is concerning for long-term viability.
Calendar
August 2025
1
Next Earnings Date
H: $-2.63
A: $-3.01
L: $-3.58
H: 158.00M
A: 113.59M
L: 67.80M
Profile
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
47.55 USD
The 39 analysts offering 1 year price forecasts for MRNA have a max estimate of 198.00 and a min estimate of 20.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in mRNA vaccine development and a key player in the global COVID-19 vaccine market, partnered with Pfizer.
Weight: 92
A direct competitor focused on developing mRNA technology platforms for vaccines and therapeutics, similar to Moderna.
Weight: 90
Partnered with BioNTech to develop and commercialize Comirnaty, a leading mRNA COVID-19 vaccine; major competitor in the broader vaccine and pharmaceutical markets.
Weight: 88
Focuses on developing mRNA-based therapeutics and vaccines, using a similar foundational technology to Moderna.